INSULET CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 201.8 USD | -2.50% |
|
-1.13% | -7.00% |
Presenter SpeechJeffrey Johnson (Analysts)Thank you. Good afternoon, [indiscernible] everyone....
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows:
- Insulin pump therapy systems (95.6%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand);
- non-insulin drug administration systems (4.4%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy).
By the end of 2022, the group will have 2 production sites located in the United States and in China.
The United States accounts for 72.2% of net sales.
Calendar
06/08/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
201.8
USD
Average target price
233.6
USD
Spread / Average Target
+15.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.00% | 14.5B | |
| -5.60% | 182B | |
| -4.45% | 102B | |
| -4.15% | 66.74B | |
| -8.63% | 45.55B | |
| +9.70% | 44.89B | |
| +6.13% | 40.62B | |
| +15.22% | 30.04B | |
| +14.80% | 24.34B | |
| -6.46% | 23.95B |
- Stock Market
- Equities
- PODD Stock
- News Insulet Corporation
- Transcript : Insulet Corporation - Special Call
